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Stress and Non-Stress Roles of 
inflammatory Signals during HSC 
emergence and Maintenance
Thomas Clapes†, Stylianos Lefkopoulos† and Eirini Trompouki*
Department of Cellular and Molecular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
Hematopoietic stem cells (HSCs) are a rare population that gives rise to almost all cells 
of the hematopoietic system, including immune cells. Until recently, it was thought that 
immune cells sense inflammatory signaling and HSCs respond only secondarily to 
these signals. However, it was later shown that adult HSCs could directly sense and 
respond to inflammatory signals, resulting in a higher output of immune cells. Recent 
studies demonstrated that inflammatory signaling is also vital for HSC ontogeny. These 
signals are thought to arise in the absence of pathogens, are active during development, 
and indispensable for HSC formation. In contrast, during times of stress and disease, 
inflammatory responses can be activated and can have devastating effects on HSCs. In 
this review, we summarize the current knowledge about inflammatory signaling in HSC 
development and maintenance, as well as the endogenous molecular cues that can 
trigger inflammatory pathway activation. Finally, we comment of the role of inflammatory 
signaling in hematopoietic diseases.
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iNTRODUCTiON
The processes of blood formation during development and its maintenance in adulthood have been 
intense topics of study for many years. Special attention is given to hematopoietic stem cells (HSCs) 
that can replenish the hematopoietic system and play pivotal roles during development and adult 
homeostasis. Given their multipotential and self-renewing capacities, HSCs are the key cell type 
in bone marrow (BM) transplantations to treat hematological diseases. Since some malignancies 
are the outcome of deregulation of the hematopoietic system, it is critical to understand how HSC 
homeostasis is maintained under steady state, but also under various stress situations. In this review, 
we will discuss the role of inflammatory cytokines in hematopoietic stem cell emergence but also 
during adulthood summarizing the current status. We will give a brief outline of the role of these 
signals in disease. The detailed ontogeny and molecular control of HSCs is beyond the scope of this 
review, but has been described in others (1–3).
Fairly and recently, inflammatory signaling and its role in HSC formation and maintenance has 
been of great interest for many researchers. For many years, it was believed that HSCs could not 
respond directly to these signals. Many groups have now shown that different cytokines and tonic 
inflammatory signaling are sensed by HSCs. These signals are required for the formation of HSCs 
during both mouse and zebrafish development. Similar cytokines are pivotal for maintaining HSC 
quiescence in adult organisms and regulating their differentiation in case of stress or disease.
Hematopoiesis is conserved between model organisms and two of them have been used 
extensively for studying both embryonic and adult hematopoiesis: zebrafish and mouse. During 
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embryonic development, they both experience different hemat-
opoietic waves (4, 5). The primitive wave is only transient and 
gives rise mainly to erythrocytes and myeloid cells, whereas 
the definitive wave gives rise to the actual HSCs through the 
conserved endothelial-to-hematopoietic transition (EHT) 
(6–9). In both organisms, EHT takes place in the aorta-gonad-
mesonephros (AGM) region. Whether EHT in mice also takes 
place in other hematopoietic organs, such as in the placenta (10) 
or in the head (11–13), is still under question. Soon after genera-
tion, HSCs migrate to the caudal hematopoietic tissue (CHT) 
in zebrafish and to the fetal liver in mouse, where they amplify. 
Finally, HSCs reach the adult hematopoietic organs, namely the 
zebrafish kidney marrow and the mouse BM, where they remain 
quiescent and few of them actively replenish the hematopoietic 
system. However, in case of stress emergency, hematopoiesis 
arises and HSCs take the lead in reestablishing the balance of 
the hematopoietic system. All studies concerning hematopoiesis 
in those two organisms not only confirm some basic anatomical 
and functional equivalences between them but also a shared 
genetic program.
iNTeRFeRONS
Interferons (IFNs) are antiviral cytokines produced by host cells 
in response to pathogens (viruses, bacteria, and parasites) and 
tumor cells. Type I IFNs (IFN-α, IFN-β) are produced by a variety 
of cell types and signal through the IFN α/β receptor (IFNAR) 
on target cells. Type II IFN (IFN-γ) is released mainly by T-cells 
and NK-cells and signal via IFN-γ receptor (IFNγR) present on 
immune cells. Finally, type III IFNs include three IFN-λ (lambda) 
molecules, called IFN-λ1, IFN-λ2, and IFN-λ3 that signal through 
IL10R2 and IFNLR1 (14).
THe iMPACT OF iNTeRFeRONS ON 
eMBRYONiC HeMATOPOieSiS
The zebrafish mutant crfb17−/− (ortholog of IFNGR1) demon-
strated a marked reduction in HSCs budding from the ventral 
wall of the dorsal aorta, compared to their crfb17+/+ siblings. 
Consistently, morpholino-mediated knockdown of the same 
receptor, as well as ifng1-2 (15) reduced the expression of an 
important marker of HSPCs, runx1, at 33 hpf (hours post fer-
tilization), indicating that IFN-γ signaling positively regulates 
HSCs. Notch signaling, a known regulator of EHT (16), was 
not sufficient to induce the EHT process in an ifng1-2-deficient 
background proving that ifng acts downstream of Notch (15). 
Interestingly, Sawamiphak et  al. also demonstrated that IFN-γ 
expression in the AGM is dependent on blood flow (15), another 
important positive regulator of HSC emergence (17). Indeed, 
ifng1-2 overexpression partially rescued this defect (15), hinting 
to an interplay between IFN signaling and mechanical signals 
that regulate blood flow.
This correlation between IFN-γ signaling and HSC emer-
gence seems to be conserved in mice (18). The numbers of HSCs 
in mouse embryos deficient in IFN-γ or IFN-γ receptor are 
decreased compared to wild type embryos. At the same time, 
transplantable HSCs are also decreased in embryos deficient 
for this receptor, all together showing an important role of this 
cytokine in HSC emergence. The conserved IFN effect on mam-
malian hematopoiesis is also supported by the fact that inflam-
matory signaling was found active in human fetal hematopoietic 
stem and progenitor cells (HSPCs) (18).
Apart from type II, type I IFNs can also regulate the process 
of embryonic hematopoiesis in both organisms, in a manner 
consistent with that of IFN-γ signaling. In particular, IFN-α in 
mice and its ortholog, IFN-ϕ, in zebrafish positively regulate 
the number of HSPCs during embryonic development (18), 
as embryos lacking IFN-α or -γ signaling harbor fewer HSPCs 
in the AGM. In another mouse study, it was shown that AGM 
HSCs exhibit lower levels of IFN-α than fetal liver HSCs, and this 
attribute can account for the lower engraftment potential of AGM 
HSCs. Treatment with IFN-α greatly enhances the repopulation 
capacity of AGM-HSCs. Mechanistically, adenine-thymine-rich 
interactive domain-3a (Arid3a) is responsible for the regulation 
of Stat1 and various IFN-responsive genes in developmental 
hematopoiesis (19).
Last, micro RNAs have been shown to regulate IFN-responsive 
genes and affect HSC development. mir-142-3p is essential for 
HSC emergence in both zebrafish and xenopus (20, 21). As shown 
in zebrafish, the main function of mir-142-3p is the downregula-
tion of irf7 (20).
THe iMPACT OF iNTeRFeRONS ON 
ADULT HeMATOPOieSiS
For decades, the role of IFNs, and in particular IFN-γ, has been 
quite controversial. In vitro studies on human cells reported that 
IFN-γ had generally a suppressive effect on hematopoietic pro-
genitors (22–25), but could synergize with other growth factors, 
such as IL-3, IL-6, EPO, and IL-1b to stimulate HSPC prolifera-
tion (26–28). Colony-forming assays of human progenitor cells 
showed that all IFNs suppressed the formation of colony-forming 
unit-granulocyte, erythroid, macrophage, megakaryocyte 
(CFU-GEMM), and burst-forming unit-erythroid (BFU-E), but 
granulocyte-macrophage (CFU-GM) were mostly responsive to 
IFNγ and less to IFNα (29, 30). Interestingly, this regulation was 
also influenced by oxygen levels (31).
One of the first in  vivo evidence demonstrating that IFNs 
could affect the adult hematopoietic progenitor compartment 
arose in a report studying lymphocytic choriomeningitis virus 
(LCMV) infection in mice. The authors observed that LCMV 
infection causes depletion of hematopoietic progenitors 
[colony-forming unit in the spleen (CFU-S)]. Interestingly, they 
demonstrated that BM aplasia following LCMV infection was 
abrogated in mice lacking both IFN-α/β receptors (32). Other 
reports have also intended to delineate the role of IFNs in vivo 
using mouse model. Sato et al. demonstrated that IFN-α treat-
ment could induce the proliferation of HSCs (side population/
LSK). Moreover, the authors showed that the interferon regula-
tory factor 2 (IRF2), a suppressor of type I IFN receptors, was 
responsible for maintaining HSC quiescence (33). Consistent 
with these findings, Essers et al. have shown that IFN-α could 
facilitate the exit of HSCs (LSK CD150+CD48−) from quiescence 
through activation of STAT-1 and AKT (34), and possibly by the 
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upregulation of c-Myc protein (35). Furthermore, it was shown 
that the tonicity of the stimulation had a great impact on HSC 
repopulating capacity. Whereas acute and short-term (three 
doses) IFN-α treatment did not impair HSC activity, chronic 
exposure (eight doses for 2  weeks) to IFN-α greatly compro-
mised HSC repopulation capacity in competitive transplantation 
assays (34). In depth studies of the acute and chronic exposure 
of HSCs to type I IFNs showed that, although brief exposure 
leads HSCs to exit quiescence, chronic exposure leads them back 
to quiescence. However, upon stress, when they are forced to 
enter cell cycle again (i.e., by transplantation), they activate a 
p53-dependent proapoptotic gene program (36), which would 
explain the suppressive effect of type-I IFNs on HSC activity.
Besides IFN-α, IFN-γ can also enhance the proliferation of 
HSPCs (LSK) in vitro and in vivo via STAT1 (37). Interestingly, 
murine BM cells cocultured with stromal cells overexpress-
ing IFN-γ failed to reconstitute congenic recipient mice upon 
transplantation (38). Mice infected with Mycobaterium avium 
have a greater proportion of proliferating HSCs (LSK CD150+) 
due to increased IFN-γ signaling. Indeed, stimulation with IFN-γ 
alone could also mediate HSC proliferation in  vivo. Moreover, 
IFN-γ-treated HSCs had decreased repopulating capacity com-
pared to untreated HSCs upon in  vivo transplantation assays 
(39). Similarly, mice infected with Ehrlichia muris also harbored 
increased HPSC (LSK) proliferation and reduction of long-term 
repopulating capacity (40). Interestingly, de Bruin et al. observed 
that IFN-γ impaired HSC maintenance by perturbing TPO sign-
aling via SOCS-1. However, the authors did not find evidence 
for enhanced proliferation of HSCs, but rather that IFN-γ could 
modulate the expression of genes involved in HSC self-renewal, 
such as Cyclin D1 (41). Type I IFN can also regulate emergency 
megakaryopoiesis by upregulating megakaryocytic proteins in 
HSCs that already transcribe mRNAs of the megakaryocytic 
program (42).
Finally, ablation of the interferon-inducible GTPase Lrg-47 
(Irgm1) inhibits baseline HSC proliferation and leads to severe 
impairment of HSCs in repopulation assays (43). Molecularly, 
it was proven that Irgm1 is a potent negative regulator of IFN 
response and that is how it exerts its action on HSCs (44).
Altogether, multiple recent reports in the literature prove that 
IFNs regulate HSC activity. However, it is still difficult to actually 
compare all these studies, as markers used to characterize HSCs 
differ (see Table 1). It is also important to note that some markers, 
such as Sca-1 (Ly6A), are upregulated following IFN-α stimula-
tion (34). It is therefore critical to link HSC phenotype to their 
actual activity, by means of in vivo transplantation assays. Finally, 
it seems that both type I and II IFNs appear to have similar effects 
on HSCs. However, it is still unclear whether both types of IFN 
have redundant function in activating HSCs upon infection. 
It is likely that they are activated by specific cues, but concrete 
evidence is still lacking.
TUMOR NeCROSiS FACTORS
Tumor necrosis factor alpha (TNFα) is a pro-inflammatory 
cytokine mainly produced by activated macrophages, lympho-
cytes, and endothelial cells (ECs). TNFα is synthesized as a 
prohormone and can be secreted after a cleavage process as a 
mature protein (45). Albeit it was first identified as a protein capa-
ble of inducing tumor cell necrosis (46), today it is also known 
that it functions as part of a number of different processes, rang-
ing from cell apoptosis (47) to fever induction (48). TNFα signals 
through two different receptors, one of them being constitutively 
and almost ubiquitously expressed (p55 receptor, also known as 
TNFR1) and the other restricting its expression to hematopoietic 
cells (p75 receptor, also known as TNFR2) (49).
THe eFFeCT OF TNFα ON eMBRYONiC 
HeMATOPOieSiS
Recently, Espín-Palazón et  al. clarified the role of TNFα in 
zebrafish embryonic hematopoiesis (50). Based on previous 
observations that this specific cytokine is necessary for embry-
onic blood vessel development (51) and the arterial origin of 
HSCs, Espín-Palazón et  al. attempted to investigate a possible 
direct correlation between HSC emergence and TNFα signaling. 
By  means of morpholino-mediated knockdown, at a dose that 
led to no vascular abnormalities, they showed that the number of 
cmyb+ cells in the dorsal aorta at 48 hpf was significantly reduced 
in tnfa- and tnfr2-, but not in tnfr1-deficient embryos (50). This 
indicates that TNFα signaling is required for HSC specification, 
and this effect is mediated through the hematopoietic-restricted 
Tnfr2. The source of TNFα was shown to be primitive neutrophils, 
answering the question about the role of these cells during early 
development, when their environment is relatively sterile.
Interestingly, ectopic provision of Notch signaling resulted in 
rescue of HSCs in both a tnfa- and a tnfr2-deficient background, 
thereby proving that Notch signals downstream of TNFα. Since 
the main mediator of TNFα is NF-κB, the authors asked whether 
NF-κB is required for HSC emergence. Blocking NF-κB resulted 
in loss of HSCs at 48 hpf and its function was suggested to lie 
downstream of Tnfr2, thus linking, for the first time, NF-κB with 
HSC emergence.
The absence of T lymphocytes by 4–5  dpf (days post fer-
tilization) in a tnfa/tnfr2-deficient background, stresses the 
importance of TNF signaling not only in HSC emergence but 
also in maintenance of nascent HSC fate, exactly like IFN-γ does 
not only affect the EHT process but also has a long-term effect 
on HSC repopulating activity. Moreover, cooperative functions 
among pro-inflammatory cytokines during embryonic hemat-
opoiesis might exist, since knockdown of both tnfa and ifng leads 
to a greater reduction of runx1 expression than the individual 
knockdown of either gene at 33 hpf (18). Interestingly, neither 
of the two cytokines was reported to have an influence on the 
primitive hematopoietic wave, implying that the role of primitive 
hematopoietic cells lies, at least partially, on the production of 
a variety of signaling molecules that will induce the subsequent 
definitive wave.
THe eFFeCT OF TNFα ON ADULT 
HeMATOPOieSiS
Pioneer studies in human cells have shown that TNFα treatment 
could inhibit the proliferation of hematopoietic progenitors 
TABLe 1 | Murine inflammatory pathways and their role in HSCs.
inflammatory 
pathways
Type of treatment effect on HSCs HSC phenotype In vivo 
transplantation?
Reference
IFN-α/β LCMV infection Pancytopenia CFU-S Yes (32)
IFN-α/β LCMV infection in INFα/β-R KO 
mice
None CFU-S Yes
IFN-α Single dose IFN-α Proliferation SP-LSK No (33)
IFN-α Single dose IFN-α Proliferation LSK CD150+ CD34− No (34)
3 doses (acute) via poly(I:C) None – Yes
8 doses (chronic) via poly(I:C) Loss of HSC activity – Yes
IFN-α 1–2 dose(s) (acute) via poly(I:C) Proliferation LSK Flk2− CD48− CD150+ – (36)
3–15 doses (chronic) via poly(I:C) Re-entry in quiescence or induced cell  
death upon transplantation
Yes
IFN-γ 2 doses (acute) Proliferation LSK No (37)
IFN-γ Coculture of MNC onto IFN-γ 
overexpressing stromal cells
Loss of HSC activity – Yes (38)
IFN-γ Single dose IFN-γ Proliferation SP-LSK (39)
Competitive transplantation of Ifnγ 
KO HSCs with WT HSCs
Better engraftment of IFN-γ KO HSCs – Yes
IFN-γ Via E. muris infection Proliferation LSK CD150+ CD34− CD135− – (40)
Loss of HSC activity – Yes
IFN-γ IFN-γ in vitro, 7 days Reduced HSC maintenance Lin-c-kit+ CD48− CD150+ Yes (41)
In vitro, 4 days, and in vivo via 
LMCV infection
Impairs HSC proliferation Yes
IFN-γ Lgr47 KO mice Reduction of HSC numbers SP or LSK Yes (43)
5-FU or mycobacterium infection of 
Lgr47 KO mice
SP Sca-1+ Yes
TNF-α Coculture with CD8+ cells Enhance LTC-IC and engraftment of HSCs LSK Yes (53)
TNF-α Competitive transplantation of WT 
HSCs and Tnfrs1a KO, Tnfrs1b KO, 
and double KO HSCs
Better engraftment of Tnfrs1a/b double KO 
HSCs
LSK Flt3− Yes (54)
3 doses TNF-α Loss of HSC activity – Yes
TNF-α Tnfrs1a KO mice Decreased HSC number, loss of HSC  
activity
LSK CD34− Yes (55)
IL-1 8 days IL-1β in liquid culture Increase proliferation and myeloid output LSK Flk2− CD48− CD150+ – (79)
Chronic (20 days) IL-1β exposure Impaired HSC activity – Yes
IL-3 Ex vivo culture Expansion of HSCs LSK or LSK CD34− Yes (80)
IL-27 Ex vivo culture (with SCF) Expansion of HSCs, myeloid differentiation LSK or LSK CD34− CD150+ No (81)
G-CSF Cfsr3 KO mice Reduction of HSPCs upon transplantation 
into WT animals
LSK Yes (98)
G-CSF G-CSF treatment in vivo Activation of dormant HSCs – No (95)
G-CSF G-CSF treatment in vivo Increased HSC proportion in endosteal 
niches
LSK CD48− CD150+ No (91)
G-CSF G-CSF treatment in vivo Increased HSC proportion, impaired 
repopulation capacity
LSK CD48− CD41− CD150+ Yes (92)
TLR2/TLR4 LPS/Pam3CSK4, treatment in vitro Skewed myeloid differentiation LSK Flk2− IL7Ra− No (63)
TLR4 LPS treatment (4–6 weeks) Increased HSC proportion, loss of  
self-renewal, myeloid differentiation
LSK Flk2− CD48− CD150+ Yes (64)
TLR Infection Pseudomonas aeruginosa Expansion of HSCs, impaired repopulating 
capacity
LSK Yes (66)
TLR LPS 4 doses Increased HSC repopulating capacity – Yes (67)
TLR2/TLR4/
MyD88
Pam3CSK4, LPS, or ODN 
treatment of chimeric mice
Differentiation of donor WT cells into 
macrophages
– Yes (68)
TLR2/TLR4 LPS/Pam3CSK4, treatment in vitro ST-HSCs and MPP cells produce  
cytokines through NF-κB
ST-HSCs (LSK CD34+ Flk2−), 
LT-HSCs (LSK CD34− Flk2−)
No (65)
5-FU, 5-fluoruracil; CFU-S, colony-forming unit in the spleen; KO, knockout; LCMV, lymphocytic choriomeningitis virus; LPS, lipopolysaccharide; LSK, Lineage+ Sca-1+c-kit+; MNC, 
mononucleated cells; MPPs, multipotent progenitors; ODN, synthetic oligodeoxynucleotides; Pam3CSK4, synthetic bacterial lipoprotein; Poly(I:C), polyinosinic:polycytidylic acid 
(synthetic dsRNA); SP, side population; ST-HSCs, short-term HSCs; WT, wild type.
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in  vitro (22, 25, 30). Dybedal et  al. have shown that human 
HSPCs (CD34+ CD38−) exposed to TNFα could not repopulate 
NOD-SCID mice upon transplantation (52). Moreover, they 
have shown that TNFα promoted myeloid differentiation 
rather than apoptosis of HSPCs. Several in  vivo studies in 
mice have clearly identified TNFα as an important physiologic 
regulator of hematopoiesis. However, some discrepancies still 
exist in the literature regarding the role of this cytokine in 
HSC activity. For instance, in  vitro assays have shown that 
TNFα production by CD8+ cells enhanced the function of 
HSPCs, notably by suppressing apoptosis (53). Additionally, 
the authors reported that, upon transplantation, hematopoi-
etic cells exposed to CD8+ produced-TNFα demonstrated a 
better engraftment (53). However, a recent study identified 
TNFα as a suppressor of HSC activity in  vivo. The authors 
carefully analyzed the repopulating capacity of HSCs isolated 
from Tnfrs1a−/−, Tnfrs1b−/−, and double knockout mice. They 
observed that, although the proportion of HSCs (LSK Flk2−) 
was comparable to wild type animals, Tnfrs1a−/− or Tnfrs1b−/− 
HSCs had an increased repopulation capacity and increased 
self-renewal activity, as demonstrated by serial transplantation 
experiments (54). This phenotype was even more pronounced 
in double knockout animals. Furthermore, they demonstrated 
that treatment of wild type mice with TNFα (three doses) 
was sufficient to suppress HSC proliferation and repopulating 
capacity. Nevertheless, it seems that the effect of TNFα may 
differ with age. Indeed, Rebel et al. noticed that the percentage 
of BM HSCs (LSK CD34−) was fourfold decreased in older 
(6 months) Tnfrs1a−/− mice. The impaired self-renewal activity 
of Tnfrs1a−/− HSCs was confirmed after secondary transplanta-
tion assays (55).
As stressed in this section, the effects of TNFα on HSCs 
are somehow complex. The comparison of the proportion of 
HSCs from one study to another is hampered by the use of 
different markers to characterize the HSC pool (see Table  1). 
However, it is clear that TNFα might act as a suppressor of HSC 
activity in vivo, and that this role might change in older mice. 
Therefore, it seems that a baseline TNFα signaling is crucial 
for the maintenance of HSC function through aging, providing 
perhaps adequate stimulation for proper HSC cell division, and 
hence, maintenance.
In addition to TNFα, other TNF-associated molecules have 
been implicated to HSC survival. Depletion of the receptor-
interacting serine/threonine-protein kinase 1 (RIPK1) stimu-
lates pro-inflammatory cytokines and results in hematopoietic 
cell death that is partially rescued by simultaneous deletion of 
Ripk3. Fetal liver cells from these mice fail to reconstitute lethally 
irradiated recipients (56). The NF-κB-associated deubiquitinase 
CYLD together with its substrate TRAF2 regulate HSC cycling 
and promote dormancy (57).
Although the role of TNF, especially during HSC mainte-
nance and stress, is still somewhat contradictory, these studies 
represent a perfect example of how a classic inflammatory 
signaling can play multiple roles during development and 
adulthood. The next step is to tightly titrate both the dosage 
and the timing of TNF to better understand its implication in 
HSC biology.
TOLL-LiKe ReCePTORS
Toll-like receptors (TLRs) are a family of transmembrane 
pattern recognition receptors that recognize a wide variety of 
pathogen- and danger-associated molecular patterns (PAMPs/
DAMPs). TLRs are located either on the plasma membrane or 
in endosomes, and signal through either MyD88-dependent or 
TRIF-dependent pathways to activate NF-κB, IRF7, or IRF3 and 
induce the expression of pro-inflammatory cytokines (58, 59).
TOLL-LiKe ReCePTOR iNFLUeNCe 
ON eMBRYONiC HeMATOPOieSiS
Regarding embryonic hematopoiesis in zebrafish, it was shown 
by He et al. that both tlr4bb and myd88 morphants demonstrated 
a reduced expression of the HSPC marker runx1 at both 24 
and 36  hpf and of the T cell marker rag1 at 4  dpf, compared 
to their wild type siblings. To confirm their observations, they 
used the clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 technology and targeted gene-specific 
promoters involved in TLR4–MyD88 signaling. This caused a 
transcriptional repression of several molecules involved in the 
pathway and led to a remarkably decreased expression of runx1, 
while the number of cmyb+kdrl+ cells in the CHT was markedly 
lower compared to wild type embryos, all together depicting the 
importance of TLR4 signaling in HSPC emergence, in a MyD88-
dependent manner (60).
Notably, morpholino-mediated knockdown of ikbaa, the 
cytoplasmic inhibitor of NF-κB, was able to rescue HSPCs in 
tlr4bb and myd88-deficient embryos, revealing that the impact of 
TLR4–MyD88 axis on HSPC emergence is mediated via NF-κB 
activation. Moreover, Notch signaling, which had already been 
reported to integrate with TLR signaling (61) and act upstream 
of Runx1 to contribute to HSPC specification (62), was proven 
to be impaired in the AGM region of TLR4–MyD88-deficient 
embryos, as reflected by the decreased expression of its target 
genes. Endothelial-specific Notch overexpression managed to 
rescue HSPCs in these embryos, showing that TLR4–MyD88–
NF-κB-mediated inflammatory signaling is upstream of endothe-
lial Notch signaling and that they, in tandem, regulate HSPC 
emergence during zebrafish embryonic development.
In the same study, the effect of TLR4–MyD88–NF-κB-
mediated inflammatory signaling was shown to be conserved in 
mouse. Immunofluorescence and qRT-PCR analysis of the AGM 
region of tlr4−/− mice, demonstrated a decreased expression of 
Runx1 at E10.5, cmyb, Il1b, and Il6 (NF-κB targets), as well as 
Notch target genes. Importantly, transplantation assays aiming 
to evaluate HSC activity, showed that 5/6 recipients transplanted 
with cells deriving from Tlr4+/− embryos were reconstituted after 
2 months, while only 1/6 recipients transplanted with cells deriv-
ing from Tlr4−/− embryos was reconstituted (60).
TOLL-LiKe ReCePTOR iNFLUeNCe 
ON ADULT HeMATOPOieSiS
Recent studies reveal that TLR ligands can exert a direct effect 
on HSC activation and hematopoietic potential. Nagai et al. have 
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found that murine HSCs (LSK Flk2− IL7Ra−) express TLR-2 and 
TLR-4 and functionally respond to receptor stimulation in vitro 
(LPS and Pan3CSK4, respectively) resulting in increased myeloid 
differentiation and enhanced cell cycling via MyD88 (63). The 
same group addressed the consequences of in vivo exposure to 
LPS. Mice injected with LPS for 4–6 weeks harbored a higher 
proportion of HSCs (LSK Flk2− CD48− CD150+) compared 
to control mice. Moreover, upon competitive transplantation 
assays, HSCs activity of LPS-treated mice showed a skewing 
toward myeloid differentiation and impaired self-renewal 
capacity as compared to untreated mice (64). Interestingly, the 
authors also observed that LPS-treated HSCs developed some 
features of aged HSCs, i.e., CD150+ expansion and lack of both 
CD86 (B7.2) and CD18 (Integrin β-2) (64). In a recent study, 
Zhao et  al. have shown that HSPCs respond to TLR stimula-
tion by producing (via NF-κB activation) cytokines to regulate 
myeloid differentiation (65). Another study of severe sepsis 
reported that, although Pseudomonas aeruginosa caused the 
expansion of HSPCs (LSK) and impaired repopulating capacity, 
they observed a block of myeloid differentiation (66). Another 
group, however, suggested a different impact of TLR signaling 
on HSCs. They described that short-term treatment with higher-
dose LPS (four doses of 35 μg, every 2 days) led to increased 
HSC repopulating capacity with no lineage bias (67). Thus, 
the dose and duration of TLR stimulation may have different 
outcomes on HSC activity, mainly promoting HSPC cycling and 
enhancing myeloid differentiation. However, despite the fact 
that HSPCs express TLRs, it was not clear yet whether direct 
recognition of pathogens by HSPCs, or changes in the micro-
environment during infection were responsible for the changes 
in hematopoiesis. To tackle this question, Megías et  al. have 
used an elegant experimental approach. They isolated wild type 
HSCs (LSK IL7Ra−) and transplanted them into lethally irradi-
ated Tlr2−/−, Tlr4−/−, or MyD88−/− recipient mice, which where 
then challenged with TLR agonists (Pam3CSK4, LPS, or ODN, 
respectively). As recipient mice could not recognize the TLR 
agonist injected, secondary effects of cytokines or soluble factors 
secreted by the microenvironment were excluded. The authors 
observed that wild type donor cells rapidly differentiated into 
macrophages, supporting the initial idea that direct stimulation 
of HSPCs via TLRs occurs in vivo (68). Other TLRs might very 
well be expressed also by HSCs. It was notably shown that TLR-9 
transcripts (predominantly expressed by lymphoid progenitors) 
were detected in HSCs (Lin−Rag1GFP−c-kithiSca1+Thy1.1lo) (69). 
Last, it will be interesting to use such TLR knockout mice, in 
order to determine whether TLR signaling also contributes to 
the maintenance of HSCs in absence of infection.
iNTeRLeUKiNS
Interleukins (ILs) are secreted proteins produced by various 
immune cell types, ranging from macrophages to T lymphocytes, 
but also other cell types, like ECs, and their role is to orchestrate 
the immune system responses (70). Among all members, IL-1 
and IL-3 have been shown to also play a role in hematopoiesis. 
The correlation between IL-1 and hematopoiesis emerged by the 
expression of this cytokine and its receptor, IL-1RI, in HSPCs 
of the BM (71–73). After early studies published from the 
lab of Hal Broxmeyer, it became evident that IL-1 would play 
synergistic roles with other factors to promote the proliferation 
and survival of more committed progenitors, in both mouse and 
humans (74, 75).
eFFeCTS OF iNTeRLeUKiNS DURiNG 
eMBRYONiC HeMATOPOieSiS
In zebrafish, it has been reported that overexpression of il1b 
can rescue the HSPC emergence defect in TLR4-deficient 
embryos, while downregulation of il1b expression in an 
NF-κB-deficient background can be rescued by knocking down 
ikbaa. Therefore, IL-1β signaling appears to be downstream 
of the TLR4–MyD88–NF-κB-mediated regulation of HSPC 
emergence (60).
When Elaine Dzierzak and her group tackled the role of IL-1 
in mouse embryonic development of HSCs, they discovered 
that IL-1R1 was detected in cells of the ventral part of the dorsal 
aortas from E11 onward. Il1r1−/− embryos demonstrated higher 
percentage of myeloid progenitor cells (CFU-G and CFU-M), 
indicating that IL-1RI-mediated signaling in the AGM region 
limits the growth of these particular progenitors. Upon trans-
plantation, they observed a slight decrease in repopulating 
cells isolated from Il1r1−/− embryos. However, the fact that the 
majority of IL-1-signaling molecules were not detected in the 
AGM at E10 indicates that IL-1 probably does participate in HSC 
emergence (76).
Since IL-3 was known to be a Runx1 target, the same group 
also attempted to decipher the role of IL-3 in mouse embryonic 
hematopoiesis (77). The expression of the cytokine and its recep-
tor was detected in major embryonic vessels at E11. Functional 
experiments divulged that, even if Runx1+/− embryos have fewer 
HSCs in the AGM region (78), IL-3 treatment managed to rescue 
(and even amplify) the number of HSCs as shown by transplanta-
tion experiments, suggesting that IL-3 signaling acts downstream 
of Runx1 (77).
eFFeCTS OF iNTeRLeUKiNS ON ADULT 
HeMATOPOieSiS
Recently, the role of chronic exposure of HSCs to IL-1 was 
delineated in a study by Pietras et al. (79). This study showed 
that IL-1 exposure of HSCs leads to the activation of a Pu1-
dependent program, which in turn results in HSC cycling and 
massive differentiation toward myeloid cells. In addition, HSCs 
lose their repopulation capacity. However, these results are tran-
sient, since withdrawal of IL-1 restores a normal phenotype (79). 
Although conflicting evidence exists, IL-3 was also shown to be 
capable of supporting HSC expansion and long-term multiline-
age repopulating capacity (80). Finally, a recent report showed 
that IL-27 exposure leads to expansion of HSPCs (LSK) while 
simultaneously promoting their differentiation toward myeloid 
cells (81).
It is evident that ILs play new exciting roles in the biology of 
HSCs, however, more studies are needed to clearly dissect the 
role of this family. It would be interesting to see how different ILs 
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or combinations of different family members interact and affect 
HSC development and maintenance.
GRANULOCYTe COLONY-STiMULATiNG 
FACTOR
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein 
that signals through its cognate receptor, granulocyte colony-
stimulating factor receptor (G-CSFR). G-CSF plays important 
roles in hematopoiesis, notably by inducing the production of 
granulocytes in response to infection (82). G-CSFR is mainly 
expressed in hematopoietic cells, and its stimulation leads to acti-
vation of downstream intracellular signaling cascades, including 
the JAK/STAT/SOCS pathway [reviewed in Ref. (83)]. Besides 
its role in granulopoiesis, G-CSF is used for clinical purposes 
to mediate HSPC mobilization from the BM into the circula-
tion. Indeed, early reports have shown that G-CSF significantly 
increased the number of HSPCs in the circulation (84). This 
potential was confirmed by others (85), and G-CSF has been 
adopted as a source of HSC for transplantations, ever since.
eFFeCTS OF G-CSF DURiNG eMBRYONiC 
HeMATOPOieSiS
Initial studies to investigate the role of G-CSF during embryonic 
development were conducted in zebrafish. The authors showed 
that in a context of emergency granulopoietic response (LPS 
stimulation), Gcsf signaling was critical to increase the number 
of neutrophils in both AGM and CHT regions. However, knock-
down of gcsfr did not impair definitive hematopoiesis (86). In a 
later study though, Hall and colleagues observed that emergency 
granulopoiesis (induced by bacterial infection) led to an increase 
in HSC numbers (87). This increase in HSCs was more likely due 
to increased cell division rather than increased EHT, and induced 
in a C/ebpb-driven Nos2a-dependent manner (87). This prolif-
erative signal was confirmed by gain-of-function experiments. 
Both G-CSFR ligands (Gcsfa and Gscfb) caused the expansion 
of runx1+ HSPCs at 24  hpf. Conversely, morpholino-mediated 
knockdown of gcsfr, gcsfa, or gcsfb significantly reduced the num-
ber of runx1+ HSPCs (88). Moreover, it seems that HSPCs in the 
CHT were also greatly increased by enhanced Gcsf signaling at 
48 hpf, indicating that both ligands play a role in the expansion of 
HSCs in the zebrafish embryo (88). Unlike in the zebrafish model, 
there is a lack of evidence in the literature for the involvement of 
G-CSF or G-CSFR (Csfr3) in promoting HSC expansion during 
embryonic development in mice.
eFFeCTS OF G-CSF ON ADULT 
HeMATOPOieSiS
Both Gcsf−/− and Csfr3−/− animals are viable, despite having 
reduced number of circulating neutrophils (89, 90). G-CSF 
administration in vivo was reported to increase the proportion 
of HSCs (LSK CD150+ CD48−) in the central marrow, but not 
in endosteal niches in the BM (91). More recently, Schuettpelz 
and colleagues confirmed the increase in the pool of HSCs 
(LSK CD150+ CD48− CD41−) in the BM upon G-CSF treat-
ment, together with loss of long-term repopulating activity due 
to induction of TLR signaling in HSCs. Interestingly, loss of 
TLR signaling or suppression of commensal flora (via antibiotic 
treatment or housing in a germ-free environment), mitigates 
the G-CSF-mediated expansion of HSCs (92).
Granulocyte colony-stimulating factor is also largely used as a 
mobilizing agent, notably by targeting cells composing the HSC 
niche, and critical for HSC maintenance (93). It is important to 
note that HSC mobilization by G-CSF is abolished in Csfr3−/− 
mice (94) and G-CSF administration is capable of activating 
dormant HSCs in vivo (95). However, chimeric mice harboring 
mixtures of Csf3r+/+ and Csfr3−/− hematopoietic cells have normal 
mobilization. This emphasizes that G-CSFR expression in HSCs 
is not required for G-CSF-mediated mobilization, and probably 
acts in trans on HSCs. This study concluded that G-CSFR expres-
sion on HSCs or stromal cells is not important for mobilization. 
Rather another unknown population of G-CSFR expressing cells 
is responsible for acting on HSC mobilization (94). Interestingly 
the Manz lab showed that at least in situations of systemic bacte-
rial stress, Tlr4-expressing ECs are the source of G-CSF and con-
tribute to emergency myelopoiesis (96, 97). The baseline numbers 
of HPSCs in Csfr3−/− mice was estimated to be similar to Csfr3+/+ 
controls, although the authors used long-term culture-initiating 
cells (LTC-ICs) to draw this conclusion. However, by competitive 
transplantation assays, the authors noticed a marked reduction of 
Csfr3−/− HSPCs (LSK) frequencies in recipient mice (98).
MACROPHAGe COLONY-STiMULATiNG 
FACTOR
Macrophage colony-stimulating factor (M-CSF) is a growth 
factor that is crucial for the proliferation, differentiation, and 
survival of monocytes and macrophages but also progenitor cells 
in the BM. Combination of human or mouse G-CSF, GM-CSG 
together, or with addition of IL3 led to increased cycling and 
elevated numbers of hematopoietic progenitors in vitro (99–101). 
The lab of Michael Sieweke brought evidence that M-CSF could 
exert a function directly on HSCs. Based on the observation that 
the monocyte/macrophage transcription factor MafB was highly 
enriched in HSCs (LSK CD34−Flk2−), but not in downstream 
progenitors, Sarrazin and colleagues investigated the effect of 
MafB deficiency on HSCs. MafB−/− HSCs were more sensitive to 
M-CSF treatment, and as a result, more prone to skewing toward 
myeloid differentiation (102). In a recent study, it was shown that 
M-CSF could directly induce endogenous PU.1 protein (a tran-
scription factor promoting myelomonocytic differentiation), in 
single HSCs in vivo and stimulates a reversible, PU.1-dependent 
myeloid differentiation (103).
iNFLAMMATiON AND 
HeMATOLOGiCAL DiSeASeS
Based on the numerous connections between inflammation and 
hematopoiesis, it should be unsurprising that deregulation of 
this interplay plays a role in hematopoietic diseases. Below, we 
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will briefly discuss some examples of HSC-associated diseases, 
and how inflammation affects the emergence, progression, or the 
outcome of the disease.
MYeLODYSPLASTiC SYNDROMeS
Myelodysplastic syndromes (MDS) (104) are a heterogeneous 
group of blood diseases mainly characterized by ineffective 
hematopoiesis, generic blood dysplasia, and a tendency toward 
leukemic transformation. The pathophysiology lying behind the 
progression of such diseases is extremely variable and, therefore, 
classified in a generic way, involving causes related to intrinsic 
abnormalities in myeloid progenitors and causes related to 
extrinsic alterations in the BM microenvironment (104, 105). 
Although the precise connection is still being elucidated, several 
studies have correlated MDS with inflammatory disorders. In a 
recent study, 4.4% of MDS patients presented also autoimmune 
manifestations (106). In addition, it was reported that inflamma-
tory bowel disease patients were diagnosed with MDS. Both these 
studies suggest an association between MDS and inflammation 
(107). However, it is still not clear whether inflammation precedes 
MDS or vice versa.
Toll-like receptor signaling is one of the pathways identified 
as a connection between inflammation and MDS. In particular, 
a number of TLRs and several signal transducers involved in 
this pathway have been found overexpressed in a high percent-
age of MDS patients (108). For example TLR2 and TLR9 are 
overexpressed in all MDS subtypes. Chronic TLR stimulation in 
mice induces phenotypes very similar to MDS (64). Among all 
TLRs that were found upregulated (109), Wei et  al. reported a 
somatic mutation of TLR2, namely TLR2-F217S, present in 11% 
of MDS patients and connected with amplified NF-κB activation, 
a transcription factor that had already been associated with the 
disease (108).
NF-κB was one of the factors expected to participate in those 
diseases due to its important role in HSC proliferation and dif-
ferentiation (110). Inhibition of its transcriptional activity was 
reported to result in apoptosis in both healthy and MDS BM 
progenitors, indicating its high significance in the maintenance 
and progression of the disease (111–113). Although induction 
of NF-κB alone is not sufficient to cause MDS, deregulation of 
NF-κB in the non-hematopoietic compartment can cause a 
myeloproliferative disorder (114).
Apart from NF-κB, TLRs are also known to induce IFN 
production. In MDS patients, IFN secretion levels were found 
severely elevated, which seems to strongly impair hematopoietic 
progenitor differentiation, for instance, erythroid differentiation 
(115) and reduce their long-term repopulating activity (116). 
Many other cytokines are induced by TLR signaling and also play 
a role in MDS. For example, TLR4 contributes to elevated TNFα 
levels in MDS patients (117).
The BM microenvironment plays a crucial role in MDS and 
is also the source or the substrate of many cytokines produced. 
MDS have been strongly associated with a specific cell type 
known as the myeloid-derived suppressor cells (MDSCs), which 
are mostly known to accumulate in cancer patients and suppress 
effector T cell response, thereby constituting one of the greatest 
defenses of a tumor against the host’s immune system (118, 119). 
These cells were also found notably increased and accumulated 
in the BM of MDS patients, where they have been proposed to 
mediate their effect mainly via secretion of several cytokines (e.g., 
IL-10) and other inflammatory effectors [e.g., reactive oxygen 
species (ROS)] leading to DNA instability and constantly active 
inflammation, which creates a permissive environment for the 
development of myelodysplasia (120).
iNHeRiTeD BONe MARROw FAiLURe
Bone marrow failure (BMF) syndromes include a group of blood 
disorders that can be either acquired or inherited and they are 
characterized by diverse kinds of defects, involving all hematopoi-
etic lineages and lead to cytopenia. Inherited BMF syndromes 
have been associated with increased risks of developing MDS, 
acute myeloid leukemia (AML), or even solid tumors (121). This 
group of rare genetic disorders involves Fanconi anemia (FA), 
Diamond–Blackfan anemia (DBA), dyskeratosis congenita (DC), 
and Shwachman–Diamond syndrome (SDS). Similar to MDS, 
BMF syndromes have also been correlated with inflammatory 
signals, and this correlation is better studied in FA (122).
During the course of this disease, a cluster of 16 genes (FANC 
genes) coding for DNA repair proteins are genetically defective 
(123–125). The prominent role of FA proteins is to respond to 
DNA damage and DNA replication stress and lead to DNA repair 
(123–125). Thus, FA is a genomic instability syndrome that can 
lead to BMF or leukemia. Patients have been often reported to 
demonstrate elevated plasma or intracellular levels of TNFα (126, 
127) that affects the production and secretion of other cytokines. 
Imbalance between different cytokines like IL-6 and GM-CSF 
affects the BM microenvironment (128). These alterations can 
cause deregulation of cellular homeostasis and are crucial for the 
progression of the disease (129–132).
Apart from mediating its role through regulation of other 
cytokine secretion, however, TNFα is also known to induce ROS, 
which represent another important factor for the disease. Several 
FA patients cannot detoxify superoxide anions, which leads to 
elevated oxidative stress. Indeed, Zhang et  al. showed that, in 
a Fancc-deficient background, TNFα-injected mice had high 
levels of oxidative stress, indicating the significant role of this FA 
protein in oxidative stress inhibition and suggesting an interplay 
between FA proteins and TNFα in the disease progression (133).
Several studies have proven that one of the reasons why 
patients experience the TNFα upregulation is TLR signaling. In 
particular, FancA- and FancC-deficient mononuclear phagocytes, 
as well as mononuclear phagocytes deriving from FA patients, 
showed upregulated levels of TLR8 and its canonical downstream 
effectors, which is known to lead to increased TNF production 
(134). On the other hand, TLR8 signaling also activates IFN 
(116), a cytokine that has also been found upregulated in FA 
patients (131), linking inflammatory signaling with this disease. 
Finally Walter et al. showed that repeated activation of dormant 
HSCs due to infection or constant blood loss, leads to DNA dam-
age. Thus HSCs lacking an intact FA DNA repair pathway cannot 
overcome constant stress and, as a result, the hematopoietic 
system collapses completely (135).
9Clapes et al. Inflammatory Signals in HSCs
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 487
LeUKeMiA
Leukemias are a group of blood cancers defined by an increased 
number of abnormal white blood cells. Leukemias can be either 
chronic or acute and can be roughly divided in four different 
categories: AML, chronic myeloid leukemia (CML), acute 
lymphoblastic leukemia (ALL), and chronic lymphoblastic leu-
kemia (CLL), based on whether the origin of the transformed 
cell is myeloid or lymphoid, but also on the characteristics of the 
disease initiation and progression. Although these leukemias 
mainly refer to differentiated hematopoietic populations, AML 
and CML arise from HSCs. CLL can be derived from more dif-
ferentiated cells but accumulating evidence shows that they may 
also originate, at least partly, from HSCs (136).
The significance of inflammation in leukemia progression and 
maintenance is not unexpected, given its known role in hemat-
opoiesis. Apart from the correlation between inflammation and 
MDS or BMF, which might result in leukemic transformation, it is 
known today that inflammatory pathways are directly connected 
with blood cancers (137–139).
One of the leukemic diseases for which the connection and 
dependence on inflammation has been well studied is AML. 
AML is the most common type of acute leukemia in adults. 
AML phenotypes can be divided in several subtypes and is 
generally characterized by the presence of hyperproliferative 
myeloid cells (140). TNFα and IFNγ have been shown to sup-
press clonogenic growth and promote differentiation in blast 
cells from AML patients (141). Studies on AML patients showed 
that the canonical NF-κB pathway is constitutively active in AML 
cells (137). Kurokawa and his group recently showed that the 
NF-κB pathway was active in leukemia-initiating cells (LICs) 
isolated from several murine myeloid leukemia models, as well 
as AML patients (142). Treatment with IκB-SR, a super repressor 
of NF-κB, led to a significant growth delay of murine myeloid 
leukemic cells. Additionally, the leukemia progression after 
transplantation of these cells into irradiated mice was delayed, 
suggesting that NF-κB is a contributing factor to the disease 
progression, but not to the survival and fate maintenance of the 
leukemic cells. Analysis of published microarray-based gene 
expression profiles and comparison between human or murine 
LICs and normal HSPCs (143–145) hinted at TNFα as the factor 
that maintains the constitutively active NF-κB pathway. Indeed, 
when LICs were treated with a TNFα-neutralizing antibody, p65 
nuclear translocation was markedly impaired, indicating that 
constitutive NF-κB activation is dependent on TNFα signaling. 
Furthermore, Tnf-deficient cells were significantly impaired in 
their potential to initiate leukemia, but NF-κB inhibition alone 
was not sufficient to inhibit leukemic progression. Thus, TNF 
may exert its function through other factors besides NF-κB 
(142). Additionally CML, ALL, and CLL cells also exhibit 
elevated NF-κB levels indicating a potential role of inflammatory 
signaling in this disease (146–150).
Other inflammatory cytokines are also prominent in leukemia 
(151). CLL patients exhibit elevated levels of IFN-γ, IL6, IL8, and 
IL10 (152–154) that can be produced by either CLL cells or from 
cells of the microenvironment. Many mutations on inflamma-
tory mediators also exist in CLL patients. For example, MYD88, 
a mediator of toll receptor signaling, is mutated in 3–10% of 
patients (155, 156).
It is evident that inflammation and leukemia are heavily 
interconnected. However we still do not know clearly the order 
of events and how inflammation affects disease progression.
DiSCUSSiON AND FUTURe DiReCTiONS
In summary, it is by now clear that inflammatory signaling arises 
as a novel regulator of HSCs emergence and maintenance, both 
under sterile conditions and in case of stress and disease. Studies 
in development and during homeostasis provide evidence that 
HSCs are affected by alteration of different cytokines (Figure 1). 
Excellent reviews referring to the subject of inflammatory signal-
ing in hematopoiesis can also complement the reading of this 
review (157–163). However, many questions are still unanswered 
and two major points include (a) the interaction of HSCs with 
other cells like niche and immune cells (158) and (b) the ligands 
that lead to inflammatory response and their source.
Diverse kinds of cells constitute the hematopoietic niche like 
osteoblasts, mesenchymal stem cells, ECs, and others (164, 165). 
For example, mesenchymal stem cells participate in the interplay 
with HSCs but can also interact with immune cells and adopt 
both pro- and anti-inflammatory roles (166–170). Immune cells 
have been found integral for HSCs both during development but 
also in adulthood. Primitive neutrophils provide crucial cytokines 
that are imperative for HSC formation during development 
(50). Macrophages play prominent roles during HSC formation 
in development but are also actively participating in the BM 
microenvironment (36, 171, 172). In depth characterization of all 
these interactions is needed to get a full overview of the interplay 
between cell populations.
The population of the niche and immune cells discussed 
above can actually be the source of different cytokines that will 
act on respective receptors on HSCs both during development 
and maintenance. Communication with other sources like 
commensal flora could also provide a source of stimulation for 
HSCs (92). Thus, most data to date support the hypothesis that 
the inflammatory ligands that affect HSCs are produced from 
various sources of the microenvironment. However, another 
hypothesis could hint to the existence of endogenous ligands 
that can play autoregulatory roles in HSCs. Lately, it has been 
shown in many systems that the epigenetic status of a cell plays 
crucial role in the expression of endogenous repetitive elements 
like endogenous retroviral elements. Members of the RIG-I-like 
receptors respond to this upregulation and can mediate an IFN 
response (173–175). It would be interesting if such a mechanism 
is used to fine tune the inflammatory milieu of the hematopoi-
etic system.
Another aspect that needs further investigation is the con-
sequence of acute versus chronic inflammatory stress on HSCs. 
Although many predicted that chronic stress will lead to HSC 
exhaustion, Pietras et al. showed that HSCs re-enter quiescence 
in conditions of chronic stress (36). However, upon a second chal-
lenge, these HSCs are much more vulnerable. Could an epigenetic 
memory, newly established on the challenged HSCs, lead them to 
such a reaction?
FiGURe 1 | inflammatory signaling is required for HSC emergence. Left panel: HSC specification in zebrafish embryos. Neutrophils produce TNFα that 
binds Tnfr2, expressed by endothelial cells (EC). Activation of Tnfr2 leads to upregulation of jag1a and activation of Notch signaling in the hemogenic endothelium 
(HE), ultimately leading to the activation of NF-κB. Alternatively, Tlr4/Myd88 also induce NF-κB, crucial for HSC specification throughout endothelial-to-
hematopoietic transition. Downstream of Notch1 activation, Ifng participates in HSC specification in a cell autonomous fashion. IL-1β signaling, downstream of the 
TLR4–MyD88–NF-κB axis has also an impact on HSC emergence as does Ifn-ϕ. Finally, Gcsf acts on newly generated HSCs and contributes to HSC proliferation; 
however, the mechanism is still unclear. Right panel: HSC specification in mouse embryos. Contrary to zebrafish embryos, it is still unclear how inflammatory 
pathways are being regulated in the developing embryo, or what are the sources of inflammatory cytokines. Nevertheless, it is clear that IFN-α, IFN-γ, as well as 
Il-1β, IL-3, and TLR4 are required for proper HSC specification, possibly engaging Notch1 signaling and Runx1 and/or NF-κB.
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Finally, understanding the inflammatory pathways in a disease 
context is of crucial importance, since this knowledge has often 
provided us with the potential to target these pathways and treat 
the diseases. To name just few examples, specific inhibition of 
TLR2 and its downstream effectors showed significant results 
in MDS patients since it induced differentiation, apoptosis, 
and impaired the clonal potential of MDS cells. OPN-305, an 
antibody against TLR2, is entering phase II clinical trials and 
holds promise for MDS treatment (176). Monoclonal antibodies 
against CD33 [gemtuzumab ozogamicin (177)] and bispecific 
antibodies like AMG330 (anti CD33 and CD3) are being explored 
for AML therapy (178). Both these antibodies redirect cytolytic 
effector T cells against leukemic cells.
In short, inflammatory signaling has a diverse and multifac-
eted role in many aspects of HSC biology from the generation of 
HSCs to their expansion and maintenance, response to stress, and 
disease. Various groups have contributed to our understanding 
of these non-immune roles of inflammatory agents, but many 
questions remain still unanswered.
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